EUVIMEDOpdag EUVIMED
Open access · CC BY 4.0

Exploring the role of apolipoprotein ε4 in progressive myoclonic epilepsy type 1

Janina Gunnar iD, Yawu Liu, Henri Eronen, Tarja Joensuu, Marja Äikiä, Jelena Hyppönen, Katri Silvennoinen, Esa Mervaala, Juhana Hakumäki, Anna-Elina Lehesjoki, Reetta Kälviäinen iD

Epileptic Disorders · 2025

DOI: 10.1002/epd2.70112 ↗

At a glance

Journal article in Epileptic Disorders, 2025. Written by Janina Gunnar and 10 co-authors. Institution: Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland. Major MEDLINE topics: Myoclonic Epilepsies, Progressive, Apolipoprotein E4. 34 references. The full text is freely available (open access, CC BY 4.0). Funded by: Saastamoinen Foundation, Folkhälsan Research Foundation, Saastamoisen säätiö.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Objective

Progressive myoclonic epilepsy type 1 (EPM1) is a neurodegenerative disease caused by biallelic variants in the cystatin B ( CSTB ) gene. Despite a progressive course, phenotype severity varies among patients, even within families. We studied the potential role of APOE ε4 in modifying phenotypic diversity in EPM1, given its established association with neurodegeneration, particularly in Alzheimer's disease.

Methods

APOE genotypes were determined for 65 genetically verified EPM1 patients homozygous for the CSTB expansion mutation. The Unified Myoclonus Rating Scale (UMRS), Quality of Life in Epilepsy Inventory‐31 questionnaire (QOLIE‐31), intellectual ability (WAIS‐R), clinical data, and quantitative neuroimaging data were compared between APOE ε4 carriers and noncarriers to assess potential correlations with EPM1 severity. Volumetric analysis was performed on MRI data, while diffusion tensor imaging (DTI) was analyzed using Tract‐Based Spatial Statistics (TBSS) and atlas‐based white matter (WM) tract region of interest (ROI) analysis.

Results

The cohort included 20 ε4 carriers (16 ε3/ε4 and 4 ε4/ε4) and 45 ε4 noncarriers (36 ε3/ε3, 8 ε2/ε3, and 1 ε2/ε2). No significant differences were found in UMRS or disease duration. Carriers had better QOLIE‐31 scores in emotional well‐being ( p = .047), energy/fatigue ( p = .048), and medical effects ( p = .024). In volumetric analysis, carriers exhibited greater preservation of bilateral hippocampal and amygdalar volumes but demonstrated more pronounced cortical thinning in the left lingual gyrus, right lateral occipital gyrus, and right posterior cingulate ( p < .05). Carriers exhibited more widespread WM degeneration in DTI, characterized by reduced fractional anisotropy (FA) and increased mean diffusivity (MD). Significance Despite greater white matter degeneration and reduced cortical thickness, APOE ε4 carriers exhibited preserved deep brain volumes and better self‐reported well‐being. This study highlights the complex interplay between genetic factors and neurodegenerative processes. Our future research aims to provide more natural history data of EPM1 and correlate long‐term phenotypic data with additional geno‐phenotypic analyses.

Subjects

MeSH terms (MEDLINE)

Myoclonic Epilepsies, ProgressiveApolipoprotein E4HumansFemaleMaleAdultMiddle AgedDiffusion Tensor ImagingCystatin BMagnetic Resonance ImagingWhite MatterQuality of Life

Author keywords

APOEEPM1ULDUnverricht‐Lundborg diseasegene

Substances

Apolipoprotein E4Cystatin B

Authors and institutions

  • Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.
  • Folkhälsan Research Center, Helsinki, Finland.
  • Medicum, University of Helsinki, Helsinki, Finland.
  • Kuopio Epilepsy Center, Kuopio University Hospital, Member of ERN EpiCARE, Kuopio, Finland.
  • Epilepsia Helsinki, Helsinki University Hospital, Member of ERN EpiCare, Helsinki, Finland.
  • Imaging Center, Kuopio University Hospital, Kuopio, Finland.

ORCID profiles: Janina Gunnar, Reetta Kälviäinen

Funding

  • Saastamoinen Foundation
  • Folkhälsan Research Foundation
  • Saastamoisen säätiö
  • Folkhälsanin Tutkimussäätiö

Cite

APA

Gunnar, J., Liu, Y., Eronen, H., Joensuu, T., Äikiä, M., Hyppönen, J., Silvennoinen, K., Mervaala, E., Hakumäki, J., Lehesjoki, A. E., & Kälviäinen, R. (2025). Exploring the role of apolipoprotein ε4 in progressive myoclonic epilepsy type 1. Epileptic Disorders. https://doi.org/10.1002/epd2.70112

Vancouver

Gunnar J, Liu Y, Eronen H, Joensuu T, Äikiä M, Hyppönen J, et al. Exploring the role of apolipoprotein ε4 in progressive myoclonic epilepsy type 1. Epileptic Disorders. 2025. doi:10.1002/epd2.70112

BibTeX
@article{Gunnar2025,
  author = {Gunnar, Janina and Liu, Yawu and Eronen, Henri and Joensuu, Tarja and Äikiä, Marja and Hyppönen, Jelena and Silvennoinen, Katri and Mervaala, Esa and Hakumäki, Juhana and Lehesjoki, Anna-Elina and Kälviäinen, Reetta},
  title = {Exploring the role of apolipoprotein ε4 in progressive myoclonic epilepsy type 1},
  journal = {Epileptic Disorders},
  year = {2025},
  doi = {10.1002/epd2.70112}
}
Start for free →